Lupin launches world's first COPD triple-combo drug Formoflo-G® MDI

Lupin launches world's first COPD triple-combo drug Formoflo-G® MDI. Lupin has launched Formoflo-G® MDI, the world’s first fixed-dose triple combination inhaler for COPD management. The product combines three active ingredients in a single dose, targeting improved patient compliance and efficacy. This launch strengthens Lupin’s respiratory portfolio in chronic lung diseases.

📊 STOCKS: $LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma